JP Morgan has raised the price target on CVS Caremark Corporation (NYSE:
CVS) from $43 to $50 and maintains its Overweight rating.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.